SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-003788
Filing Date
2022-01-13
Accepted
2022-01-13 07:00:56
Documents
15
Period of Report
2022-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm222698d1_8k.htm   iXBRL 8-K 40764
2 EXHIBIT 2.1 tm222698d1_ex2-1.htm EX-2.1 369598
3 EXHIBIT 99.1 tm222698d1_ex99-1.htm EX-99.1 21112
7 GRAPHIC tm222698d1_ex99-1img001.jpg GRAPHIC 5313
  Complete submission text file 0001104659-22-003788.txt   701819

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vyne-20220112.xsd EX-101.SCH 3060
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20220112_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20220112_pre.xml EX-101.PRE 22613
9 EXTRACTED XBRL INSTANCE DOCUMENT tm222698d1_8k_htm.xml XML 3708
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 22527827
SIC: 2834 Pharmaceutical Preparations